Brentuximab Vedotin et chimiothérapie combinée dans le traitement des enfants et des jeunes adultes atteints d'un lymphome de Hodgkin de stade IIB, IIIB, IVA ou IVB
Une étude randomisée de phase 3 sur le brentuximab védotine (SGN-35) pour le lymphome hodgkinien classique à haut risque nouvellement diagnostiqué (cHL) chez les enfants et les jeunes adultes
This phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating children and young adults with stage IIB with bulk, stage IIIB, IVA, or IVB Hodgkin lymphoma. Combinations of biological substances in brentuximab vedotin may be able to carry cancer-killing substances directly to Hodgkin lymphoma cells. Chemotherapy drugs, such as doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if combination chemotherapy is more effective with or without brentuximab vedotin in treating children with high-risk Hodgkin lymphoma.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
- Autre: Laboratory Biomarker Analysis
- Autre: Quality-of-Life Assessment
- Médicament: Cyclophosphamide
- Médicament: Doxorubicin Hydrochloride
- Médicament: Prednisone
- Médicament: Vincristine Sulfate
- Autre: Questionnaire Administration
- Médicament: Brentuximab Vedotin
- Médicament: Etoposide
- Autre: Pharmacological Study
- Biologique: Bleomycin Sulfate
- Médicament: Methylprednisolone
Description détaillée
PRIMARY OBJECTIVE:
I. To assess the event free survival (EFS) of a novel regimen incorporating brentuximab vedotin (Bv; Adcetris) in the chemotherapy backbone of doxorubicin hydrochloride (doxorubicin) (Adriamycin), vincristine sulfate (vincristine), etoposide, prednisone and cyclophosphamide (Bv-AVEPC) in newly diagnosed high-risk classical Hodgkin lymphoma (cHL) compared to those treated with Adriamycin, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide (ABVE-PC).
SECONDARY OBJECTIVES:
I. To determine whether children/young adults with high-risk cHL treated with Bv-AVEPC have a higher rate of early response (determined by fludeoxyglucose F 18 [FDG]-positron emission tomography [PET]) and a reduction in protocol directed radiation therapy (RT) compared to those treated with ABVE-PC.
II. To compare the rate of neuropathy (>= grade 3) among patients treated on the Bv-AVEPC (experimental arm) to patients treated on the ABVE-PC (standard arm).
EXPLORATORY OBJECTIVES:
I. To validate and compare the Childhood Hodgkin International Prognostic Score (CHIPS) to conventional Ann Arbor stage (stages II B with bulk, III B, IV A or B) in predicting outcome in high-risk childhood cHL.
II. To determine the incidence of preferentially expressed antigen in melanoma (PRAME) and testis-specific antigens in Epstein-Barr virus (EBV)- cHL tumors and the incidence of EBV antigens (Epstein-Barr nuclear antigen 1 [EBNA1], Epstein-Barr virus latent membrane protein 1 [LMP1], large multifunctional peptidase 2 [LMP2]) in EBV+ cHL tumors, with the goal of developing strategies to integrate cellular therapy into treatment for newly diagnosed high-risk cHL. (Biology) III. To incorporate qualitative visual FDG-PET into response-directed treatment algorithms and explore quantitative FDG-PET and computed tomography (CT) definitions of tumor burden and response for incorporation into next generation pediatric cHL risk-stratification schemes, exploring the extension of these algorithms to young adults. (Imaging) IV. To evaluate the reduction in normal tissue irradiation associated with the current treatment approach compared to the volume of historic involved field radiation therapy (IFRT) fields. (Radiation Therapy) V. To evaluate EFS and patterns of relapse following protocol-specified RT utilization and treatment volumes. (Radiation Therapy) VI. To characterize the extent of chemotherapy induced peripheral neuropathy (CIPN), as reported by patients and parent proxies, through serial administration of the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group-Neurotoxicity (FACT-GOG-NTX). (Patient Reported Outcomes [PRO] of Peripheral Neuropathy and Health-Related Quality of Life) VII. To describe the Health-Related Quality of Life (HRQL) consequences of peripheral neuropathy over time by correlating total neuropathy scale scores with the individual items with the Child Health Ratings Inventories (CHRIs)-Global scale (e.g., physical health, pain, emotional functioning). (PRO of Peripheral Neuropathy and Health-Related Quality of Life) VIII. To perform a cross validation of the FACT-GOG-NTX with the Total Neuropathy Score-Pediatric Vincristine (TNS-PV) to determine the performance of both measures with the use of brentuximab vedotin in a limited institutional approach in children and adolescents with cHL. (PRO of Peripheral Neuropathy and Health-Related Quality of Life) IX. To assess the resource use and cost implications of Bv in combination with chemotherapy and radiotherapy (RT) for newly diagnosed high-risk cHL in children and young adults. (Economic) X. To estimate the risk of relapse among rapidly responding lesions (RRL) subjects that have at least one lesion that is Deauville 3 at PET 2. (Follow-up of Deauville score 3 lesions on FDG-PET imaging [confirmed by central imaging review]) XI. To characterize the pharmacokinetics of brentuximab vedotin in children < 13 years of age.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I (ABVE-PC): Patients receive doxorubicin hydrochloride intravenously (IV) over on days 1-2, bleomycin sulfate IV or subcutaneously (SC) on days 1 and 8, vincristine sulfate IV on days 1 and 8, etoposide IV on days 1-3, prednisone orally (PO) twice daily (BID) or methylprednisolone IV on days 1-7, and cyclophosphamide IV on days 1 and 2.
ARM II (Bv-AVEPC): Patients receive brentuximab vedotin IV on day 1. Patients also receive doxorubicin hydrochloride, etoposide, prednisone or methylprednisolone, and cyclophosphamide as in Arm I and vincristine sulfate IV on day 8.
In both arms, treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity. Granulocyte simulating factor (GCSF) or equivalent is given on both arms.
After completion of study treatment, patients are followed up at 3, 6, 9, 12, 18, 24, 30, 36, and 48 months.
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Québec, Canada, G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Alberta Children's Hospital
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
Kingston, Ontario, Canada, K7L 2V7
- Kingston Health Sciences Centre
-
London, Ontario, Canada, N6A 5W9
- Children's Hospital
-
Ottawa, Ontario, Canada, K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal, Quebec, Canada, H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Saskatoon Cancer Centre
-
-
-
-
-
Caguas, Porto Rico, 00726
- HIMA San Pablo Oncologic Hospital
-
San Juan, Porto Rico, 00926
- University Pediatric Hospital
-
San Juan, Porto Rico, 00912
- San Jorge Children's Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35233
- Children's Hospital of Alabama
-
Mobile, Alabama, États-Unis, 36604
- USA Health Strada Patient Care Center
-
-
Alaska
-
Anchorage, Alaska, États-Unis, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Mesa, Arizona, États-Unis, 85202
- Banner Children's at Desert
-
Phoenix, Arizona, États-Unis, 85016
- Phoenix Childrens Hospital
-
Tucson, Arizona, États-Unis, 85719
- Banner University Medical Center - Tucson
-
-
Arkansas
-
Little Rock, Arkansas, États-Unis, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Downey, California, États-Unis, 90242
- Kaiser Permanente Downey Medical Center
-
Duarte, California, États-Unis, 91010
- City of Hope Comprehensive Cancer Center
-
Loma Linda, California, États-Unis, 92354
- Loma Linda University Medical Center
-
Long Beach, California, États-Unis, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, États-Unis, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, États-Unis, 90027
- Children's Hospital Los Angeles
-
Madera, California, États-Unis, 93636
- Valley Children's Hospital
-
Oakland, California, États-Unis, 94611
- Kaiser Permanente-Oakland
-
Orange, California, États-Unis, 92868
- Children's Hospital of Orange County
-
Sacramento, California, États-Unis, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, États-Unis, 95817
- University of California Davis Comprehensive Cancer Center
-
San Diego, California, États-Unis, 92123
- Rady Children's Hospital - San Diego
-
San Diego, California, États-Unis, 92134
- Naval Medical Center -San Diego
-
Santa Barbara, California, États-Unis, 93102
- Santa Barbara Cottage Hospital
-
Torrance, California, États-Unis, 90502
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Children's Hospital Colorado
-
Denver, Colorado, États-Unis, 80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
-
Connecticut
-
Hartford, Connecticut, États-Unis, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, États-Unis, 06520
- Yale University
-
-
Delaware
-
Wilmington, Delaware, États-Unis, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20010
- Children's National Medical Center
-
Washington D.C., District of Columbia, États-Unis, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Fort Lauderdale, Florida, États-Unis, 33316
- Broward Health Medical Center
-
Fort Myers, Florida, États-Unis, 33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville, Florida, États-Unis, 32610
- UF Health Cancer Institute - Gainesville
-
Hollywood, Florida, États-Unis, 33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville, Florida, États-Unis, 32207
- Nemours Children's Clinic-Jacksonville
-
Miami, Florida, États-Unis, 33155
- Nicklaus Children's Hospital
-
Miami, Florida, États-Unis, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, États-Unis, 33176
- Miami Cancer Institute
-
Orlando, Florida, États-Unis, 32827
- Nemours Children's Hospital
-
Orlando, Florida, États-Unis, 32803
- AdventHealth Orlando
-
Orlando, Florida, États-Unis, 32806
- Arnold Palmer Hospital for Children
-
Pensacola, Florida, États-Unis, 32504
- Nemours Children's Clinic - Pensacola
-
St. Petersburg, Florida, États-Unis, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, États-Unis, 33606
- Tampa General Hospital
-
Tampa, Florida, États-Unis, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
West Palm Beach, Florida, États-Unis, 33407
- Saint Mary's Medical Center
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Augusta, Georgia, États-Unis, 30912
- Augusta University Medical Center
-
Savannah, Georgia, États-Unis, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, États-Unis, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, États-Unis, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, États-Unis, 60612
- University of Illinois
-
Chicago, Illinois, États-Unis, 60611
- Lurie Children's Hospital-Chicago
-
Maywood, Illinois, États-Unis, 60153
- Loyola University Medical Center
-
Oak Lawn, Illinois, États-Unis, 60453
- Advocate Children's Hospital-Oak Lawn
-
Park Ridge, Illinois, États-Unis, 60068
- Advocate Children's Hospital-Park Ridge
-
Peoria, Illinois, États-Unis, 61637
- OSF Children's Hospital of Illinois
-
Springfield, Illinois, États-Unis, 62702
- Southern Illinois University School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Riley Hospital for Children
-
Indianapolis, Indiana, États-Unis, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
-
Iowa
-
Des Moines, Iowa, États-Unis, 50309
- Blank Children's Hospital
-
Iowa City, Iowa, États-Unis, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, États-Unis, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, États-Unis, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis, 70121
- Ochsner Medical Center Jefferson
-
New Orleans, Louisiana, États-Unis, 70118
- Children's Hospital New Orleans
-
-
Maine
-
Bangor, Maine, États-Unis, 04401
- Eastern Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, États-Unis, 21215
- Sinai Hospital of Baltimore
-
Baltimore, Maryland, États-Unis, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda, Maryland, États-Unis, 20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02111
- Tufts Children's Hospital
-
Springfield, Massachusetts, États-Unis, 01199
- Baystate Medical Center
-
Worcester, Massachusetts, États-Unis, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- C S Mott Children's Hospital
-
Detroit, Michigan, États-Unis, 48201
- Wayne State University/Karmanos Cancer Institute
-
Detroit, Michigan, États-Unis, 48236
- Henry Ford Health Saint John Hospital
-
East Lansing, Michigan, États-Unis, 48823
- Michigan State University
-
Flint, Michigan, États-Unis, 48503
- Hurley Medical Center
-
Grand Rapids, Michigan, États-Unis, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo, Michigan, États-Unis, 49007
- Bronson Methodist Hospital
-
Royal Oak, Michigan, États-Unis, 48073
- Corewell Health Children's
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, États-Unis, 55455
- University of Minnesota/Masonic Cancer Center
-
Rochester, Minnesota, États-Unis, 55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson, Mississippi, États-Unis, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, États-Unis, 65212
- University of Missouri Children's Hospital
-
Kansas City, Missouri, États-Unis, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, États-Unis, 63110
- Washington University School of Medicine
-
St Louis, Missouri, États-Unis, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, États-Unis, 63104
- Cardinal Glennon Children's Medical Center
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, États-Unis, 68114
- Children's Hospital and Medical Center of Omaha
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, États-Unis, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, États-Unis, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, États-Unis, 89102
- University Medical Center of Southern Nevada
-
-
New Hampshire
-
Lebanon, New Hampshire, États-Unis, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, États-Unis, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, États-Unis, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, États-Unis, 08901
- Saint Peter's University Hospital
-
New Brunswick, New Jersey, États-Unis, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark, New Jersey, États-Unis, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, États-Unis, 07503
- Saint Joseph's Regional Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, États-Unis, 12208
- Albany Medical Center
-
Buffalo, New York, États-Unis, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, États-Unis, 11501
- NYU Langone Hospital - Long Island
-
New Hyde Park, New York, États-Unis, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, États-Unis, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, États-Unis, 10029
- Mount Sinai Hospital
-
New York, New York, États-Unis, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, États-Unis, 10065
- NYP/Weill Cornell Medical Center
-
New York, New York, États-Unis, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, États-Unis, 14642
- University of Rochester
-
Stony Brook, New York, États-Unis, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, États-Unis, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, États-Unis, 10467
- Montefiore Medical Center - Moses Campus
-
-
North Carolina
-
Asheville, North Carolina, États-Unis, 28801
- Mission Hospital
-
Chapel Hill, North Carolina, États-Unis, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, États-Unis, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, États-Unis, 28204
- Novant Health Presbyterian Medical Center
-
Durham, North Carolina, États-Unis, 27710
- Duke University Medical Center
-
Greenville, North Carolina, États-Unis, 27834
- East Carolina University
-
Winston-Salem, North Carolina, États-Unis, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, États-Unis, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, États-Unis, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, États-Unis, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, États-Unis, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, États-Unis, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, États-Unis, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, États-Unis, 45404
- Dayton Children's Hospital
-
Toledo, Ohio, États-Unis, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Oregon Health and Science University
-
Portland, Oregon, États-Unis, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, États-Unis, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, États-Unis, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Danville, Pennsylvania, États-Unis, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, États-Unis, 17033
- Penn State Children's Hospital
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, États-Unis, 19134
- Saint Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, États-Unis, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, États-Unis, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, États-Unis, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, États-Unis, 29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, États-Unis, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Chattanooga, Tennessee, États-Unis, 37403
- T C Thompson Children's Hospital
-
Knoxville, Tennessee, États-Unis, 37916
- East Tennessee Childrens Hospital
-
Nashville, Tennessee, États-Unis, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, États-Unis, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Austin, Texas, États-Unis, 78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi, Texas, États-Unis, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, États-Unis, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, États-Unis, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, États-Unis, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, États-Unis, 76104
- Cook Children's Medical Center
-
Houston, Texas, États-Unis, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, États-Unis, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock, Texas, États-Unis, 79410
- Covenant Children's Hospital
-
Lubbock, Texas, États-Unis, 79415
- UMC Cancer Center / UMC Health System
-
San Antonio, Texas, États-Unis, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, États-Unis, 78207
- Children's Hospital of San Antonio
-
San Antonio, Texas, États-Unis, 78229
- Methodist Children's Hospital of South Texas
-
Temple, Texas, États-Unis, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84113
- Primary Children's Hospital
-
-
Vermont
-
Burlington, Vermont, États-Unis, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22908
- University of Virginia Cancer Center
-
Falls Church, Virginia, États-Unis, 22042
- Inova Fairfax Hospital
-
Norfolk, Virginia, États-Unis, 23507
- Children's Hospital of The King's Daughters
-
Richmond, Virginia, États-Unis, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Seattle, Washington, États-Unis, 98105
- Seattle Children's Hospital
-
Spokane, Washington, États-Unis, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, États-Unis, 98405
- Mary Bridge Children's Hospital and Health Center
-
Tacoma, Washington, États-Unis, 98431
- Madigan Army Medical Center
-
-
West Virginia
-
Charleston, West Virginia, États-Unis, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Morgantown, West Virginia, États-Unis, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Green Bay, Wisconsin, États-Unis, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison, Wisconsin, États-Unis, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marshfield, Wisconsin, États-Unis, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, États-Unis, 53226
- Children's Hospital of Wisconsin
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Patients with newly diagnosed, pathologically confirmed cHL meeting one of the following Ann Arbor stages are eligible:
-
Stage IIB with bulk
-
Stage IIIB
-
Stage IVA
-
Stage IVB
- If study eligibility by staging is uncertain, consultation with Imaging and Radiation Oncology Core (IROC) Rhode Island (RI) may be obtained prior to study enrollment
-
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows (performed within 14 days prior to enrollment):
- 2 to < 6 years: male 0.8 mg/dL, female 0.8 mg/dL
- 6 to < 10 years: male 1 mg/dL, female 1 mg/dL
- 10 to < 13 years: male 1.2 mg/dL, female 1.2 mg/dL
- 13 to < 16 years: male 1.5 mg/dL, female 1.4 mg/dL
- >= 16 years: male 1.7 mg/dL, female 1.4 mg/dL
-
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (performed within 14 days prior to enrollment)
-
Serum glutamic oxaloacetic transaminase (SGOT) (aspartate transaminase [AST]) or serum glutamate pyruvate transaminase (SGPT) (alanine transaminase [ALT]) < 2.5 x upper limit of normal (ULN) for age (performed within 14 days prior to enrollment)
-
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by radionuclide angiogram
-
Forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from Hodgkin lymphoma (HL)
-
For children who are unable to cooperate for PFTs, the criteria are: no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry reading of > 92% on room air
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
- Patients with nodular lymphocyte-predominant HL
- Patients with an immunodeficiency that existed prior to diagnosis, such as primary immunodeficiency syndromes, organ transplant recipients and children on current systemic immunosuppressive agents are not eligible
- Patients who are pregnant; (since fetal toxicities and teratogenic effects have been noted for several of the study drugs, a negative pregnancy test is required for female patients of childbearing potential)
- Lactating females who plan to breastfeed
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for 30 days after the last dose of chemotherapy
- Patients known to be positive for human immunodeficiency virus (HIV) are not eligible
- Patients who have received any previous chemotherapy or radiation therapy are not eligible
- Patients who received systemic corticosteroids within 28 days of enrollment on this protocol, except as specified, are not eligible
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Comparateur actif: Arm I (ABVE-PC)
Patients receive doxorubicin hydrochloride IV over on days 1-2, bleomycin sulfate IV or SC on days 1 and 8, vincristine sulfate IV on days 1 and 8, etoposide IV on days 1-3, prednisone orally PO BID or methylprednisolone IV on days 1-7, and cyclophosphamide IV on days 1 and 2. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity. |
Correlative studies Ancillary studies
Autres noms:
Given IV
Autres noms:
Given IV
Autres noms:
Given PO
Autres noms:
Given IV
Autres noms:
Ancillary studies Given IV
Autres noms:
Correlative studies Given IV or SC
Autres noms:
Given IV
Autres noms:
|
|
Expérimental: ARM II (Bv-AVEPC)
Patients receive brentuximab vedotin IV on day 1. Patients also receive doxorubicin hydrochloride, etoposide, prednisone or methylprednisolone, and cyclophosphamide as in Arm I and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity. |
Correlative studies Ancillary studies
Autres noms:
Given IV
Autres noms:
Given IV
Autres noms:
Given PO
Autres noms:
Given IV
Autres noms:
Ancillary studies Given IV
Autres noms:
Given IV
Autres noms:
Correlative studies Given IV
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Event Free Survival (EFS), Where Events Include Disease Progression or Relapse, Second Malignancy, or Death
Délai: Up to 48 months after the last enrollment
|
Primary analysis will be based 1-sided log rank test comparison of EFS curves between the 2 randomized arms per intention-to-treat principle. Progression is defined as an ≥50% increase of in the product of the perpendicular diameters of any of the involved nodes or nodal masses or focal organ lesions in sites that were persistently PET positive; or recurrent PET positive lesions (Deauville 4, 5) in sites that had previously been PET negative regardless of change of size, as was the development of new PET avid measurable lesion(s) >1.5cm in any axis, or new sites of assessable disease. Relapse is defined in patients who achieved a prior CR but subsequently has an increase of ≥50% of the PPD in prior nodal or extranodal sites in a recurrently PET positive lesion(s), or the development of new measurable lesion(s) >1.5cm in any axis, or new sites of assessable disease. Second malignancy is defined based on report of a cancer that is not considered to be classic Hodgkin Lymphoma. |
Up to 48 months after the last enrollment
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentages of Patients With Early Response Defined as no Slow Responding Lesions (SRL) and no Progressive Disease (PD) at Any Disease Sites Determined by Positron Emission Tomography (PET) Per Deauville Criteria Through Central Review
Délai: After 42 days of chemotherapy
|
The percentages of patients (with available PET scan) with no SRL and no PD will be compared between the two randomized arms to see if brentuximab vedotin in the chemotherapy backbone of doxorubicin hydrochloride, vincristine sulfate, etoposide, prednisone and cyclophosphamide (Bv-AVEPC) arm has a higher rate of early response compared to doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide (ABVE-PC) arm. Two-sample Z test of proportions at 1-sided alpha level of 0.05 will be used for these comparisons. |
After 42 days of chemotherapy
|
|
Percentages of Patients Experiencing Grade 3+ Peripheral Neuropathy Assessed by Modified Balis Scale
Délai: From the enrollment of the patient to the time of analysis or the last follow-up; an average of 3.6 years.
|
The percentages of patients experiencing grade 3+ peripheral neuropathy assessed by the treating clinician using the modified Balis scale. The "Modified Balis scale of Pediatric Neuropathy" allows clinicians to assign a score for sensory or motor neuropathy symptoms separately. Scores range from 1 to 4 with 1 being the least symptomatic state and 4 indicating a severe debility. The percentages of patients (with a score >/=3) will be compared between the 2 arms by two-sample Z test at 1-sided alpha level of 0.05. |
From the enrollment of the patient to the time of analysis or the last follow-up; an average of 3.6 years.
|
Autres mesures de résultats
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Childhood International Prognostic Score (CHIPS) Score
Délai: Baseline
|
CHIPS will be computed for all patients and summarized by descriptive statistics. Will examine the association between CHIPS and early response by cross-tabulations and Chi-square tests within each arm separately, as well as logistic regression model where early response is the outcome variable and CHIPS the predictor variable combining the 2 arms with adjustment for randomized chemotherapy. |
Baseline
|
|
Dose of Radiation Received by Normal Tissues Following Chemotherapy on Either Study Arm
Délai: Up to 48 months
|
Descriptive statistics will be used to summarize RT doses received by normal tissues on this study. Two-sample t-test will be used to compare the doses received on this study to those on prior studies. |
Up to 48 months
|
|
Efficacy of Involved Site Radiotherapy (ISRT) by Analyzing the Event-free Survival of Patients Treated With Response-adapted ISRT and by Evaluating Patterns of Relapse Following ISRT
Délai: Up to 3 years
|
EFS for patients on each arm as well as those receiving ISRT or those with slow early response (SER) on each arm will be estimated. One-sample log rank test will be used to compare the observed EFS to the assumed baseline of 82% at 3 years to see if the observed EFS is significantly lower than the projection in these subsets. |
Up to 3 years
|
|
Risk of Relapse Among RRL Subjects That Have at Least One Lesion That is Deauville 3 at PET 2
Délai: Up to 48 months after the last enrollment
|
The risk of relapse for cases that are RRL, but have Deauville 3 lesions, will be compared to those that are classified as complete metabolic response at PET2 with solely Deauville 1 or 2 lesions with K-sample test. |
Up to 48 months after the last enrollment
|
|
Pharmacokinetic (PK) Analyses
Délai: Pre-dose and end of infusion on day 1, days 2, 3, 8, and 15 of cycle 4 and pre-dose on day 1 and day 22 of cycle 5 (each cycle = 21 days)
|
PK concentration time profile will be evaluated. |
Pre-dose and end of infusion on day 1, days 2, 3, 8, and 15 of cycle 4 and pre-dose on day 1 and day 22 of cycle 5 (each cycle = 21 days)
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Les enquêteurs
Les enquêteurs
- Chercheur principal: Sharon M Castellino, Children's Oncology Group
Publications et liens utiles
Publications générales
- Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, Cho S, Wu Y, Punnett A, Dave H, Henderson TO, Hoppe BS, Charpentier AM, Keller FG, Kelly KM. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022 Nov 3;387(18):1649-1660. doi: 10.1056/NEJMoa2206660.
- Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM; COG Hodgkin Lymphoma Committee. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28.
- Tie X, Shin M, Lee C, Perlman SB, Huemann Z, Weisman AJ, Castellino SM, Kelly KM, McCarten KM, Alazraki AL, Hu J, Cho SY, Bradshaw TJ. Automatic Quantification of Serial PET/CT Images for Pediatric Hodgkin Lymphoma Using a Longitudinally Aware Segmentation Network. Radiol Artif Intell. 2025 May;7(3):e240229. doi: 10.1148/ryai.240229.
- Pabari R, McCarten K, Flerlage J, Lai H, Mauz-Korholz C, Dieckmann K, Palese M, Kaste S, Castellino SM, Kelly KM, Stoevesandt D, Kurch L. Hodgkin lymphoma involving the extra-axial CNS: an AHOD1331, PHL-C1, and PHL-C2 report from the COG and EuroNet-PHL. Blood Adv. 2024 Sep 24;8(18):4856-4865. doi: 10.1182/bloodadvances.2023012346.
- Williams AM, Rodday AM, Pei Q, Henderson TO, Keller FG, Punnett A, Kelly KM, Castellino SM, Parsons SK. Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study. J Clin Oncol. 2024 Oct;42(28):3330-3338. doi: 10.1200/JCO.24.00038. Epub 2024 Jul 26.
- Parsons SK, Rodday AM, Pei Q, Keller FG, Wu Y, Henderson TO, Cella D, Kelly KM, Castellino SM. Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study. J Patient Rep Outcomes. 2023 Nov 10;7(1):113. doi: 10.1186/s41687-023-00653-0.
- Hoppe BS, McCarten KM, Pei Q, Kessel S, Alazraki A, Mhlanga JC, Lai HA, Eutsler E, Hodgson DC, Roberts KB, Charpentier AM, Keller FG, Voss SD, Wu Y, Cho SY, Kelly KM, Castellino SM. Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023 Aug 1;116(5):1025-1030. doi: 10.1016/j.ijrobp.2023.02.020. Epub 2023 Mar 2.
- Williams AM, Rodday AM, Renfro LA, Wu Y, Henderson TO, Keller FG, Punnett A, Hodgson D, Kelly KM, Castellino SM, Parsons SK. Group-based trajectories of health-related quality of life among pediatric patients with high-risk Hodgkin lymphoma. J Natl Cancer Inst. 2025 Oct 1;117(10):2112-2119. doi: 10.1093/jnci/djaf197.
- Toner K, Renfro LA, Dave H, Pezzella G, Pei Q, Giulino-Roth L, Horton T, Keller FG, Kelly KM, Castellino SM, Bollard CM. Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma. Blood Adv. 2026 Jan 13;10(1):183-191. doi: 10.1182/bloodadvances.2025016797.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Peptides
- Acides aminés, peptides et protéines
- Oligopeptides
- Protéines
- Produits chimiques organiques
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Hydrocarbures
- Hydrocarbures, cyclique
- Glucides
- Alcaloïdes
- Podophyllotoxine
- Tétrahydronaphtalènes
- Naphtalenes
- Hydrocarbures aromatiques polycycliques
- Hydrocarbures, aromatique
- Composés polycycliques
- Glucosides
- Glycosides
- Indoles
- Anticorps, monoclonal, humanisé
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Prégnades
- Grossesse
- Stéroïdes
- Composés à anneau fusionné
- Moutards phosphoramides
- Composés de moutarde d'azote
- Composés moutarde
- Hydrocarbures, halogénés
- Phosphoramides
- Composés organophosphores
- Grossissement
- Grossissements
- Alcaloïdes Vinca
- Alcaloïdes de la secologane tryptamine
- Alcaloïdes indole
- Indolizidines
- Indolizines
- Anthracyclines
- Naphtacènes
- Aminoglycosides
- Glycoconjuguis
- Daunorubicine
- Glycopeptides
- Prednisolone
- Brentuximab Védotine
- Prednisone
- Cyclophosphamide
- Étoposide
- Doxorubicine
- Vincristine
- Méthylprednisolone
- Bléomycine
- deltacortene
- prednylidene
- exifone
- Medrol Veriderm
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- NCI-2014-01223
- U10CA180886 (Subvention/contrat des NIH des États-Unis)
- NCI-2014-01223 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
- s15-00950
- AHOD1331 (Autre identifiant: CTEP)
- AHOD1331 (Autre identifiant: Children's Oncology Group)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .